Birmingham, Alabama
CNS medication trials in Birmingham, AL
26 CNS medication studies are recruiting participants at sites in Birmingham as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Birmingham at a glance
- 26 studies are recruiting at a site in Birmingham.
- By phase: Early Phase 1 (1), Phase 1 (1), Phase 1/2 (1), Phase 2 (5), Phase 2/3 (2), Phase 3 (12), Phase 4 (3), No phase (1). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (19), university, hospital or other (5), government (2).
- By research area: Depression (8), Parkinson's Disease (6), Multiple Sclerosis (5), Migraine (3), Epilepsy (2), ADHD (1), Schizophrenia (1).
- Most recent update to one of these records: November 17, 2026.
Depression studies recruiting in Birmingham
Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Study site
- University of Alabama
- Registry record
- NCT07226661 · updated
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Phase 3
- Ages 18 to 85
- All sexes
- Sponsor
- Cybin IRL Limited
- Study site
- UAB Psychiatry and Behavioral Neurology
- Registry record
- NCT06793397 · updated
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Phase 2
- Ages 18 to 80
- All sexes
- Sponsor
- Reunion Neuroscience Inc
- Study site
- UAB, Psychiatry and Behavioral Neurology
- Registry record
- NCT07002034 · updated
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- Phase 3
- Ages 12 to 17
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- University of Alabama at Birmingham
- Registry record
- NCT07227454 · updated
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- University of Alabama at Birmingham - School of Medicine
- Registry record
- NCT07775300 · updated
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- VA Office of Research and Development
- Study site
- Birmingham VA Medical Center, Birmingham, AL
- Registry record
- NCT07226232 · updated
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Phase 2
- Ages 18 to 64
- All sexes
- Sponsor
- Syndeio Biosciences, Inc
- Study site
- University of Alabama at Birmingham
- Registry record
- NCT06547489 · updated
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- Autobahn Therapeutics, Inc.
- Study site
- Autobahn Site #131
- Registry record
- NCT06633016 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Birmingham, AL on ClinicalTrials.gov.
Schizophrenia studies recruiting in Birmingham
Biomarkers to Enhance Early Schizophrenia Treatment
- Phase 4
- Ages 18 to 35
- All sexes
- Sponsor
- Northwell Health
- Study site
- The University of Alabama at Birmingham
- Registry record
- NCT06969755 · updated
Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Birmingham, AL on ClinicalTrials.gov.
ADHD studies recruiting in Birmingham
Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints
- Phase 4
- Ages 18 to 65
- All sexes
- Sponsor
- VA Office of Research and Development
- Study site
- Birmingham VA Medical Center, Birmingham, AL
- Registry record
- NCT05776056 · updated
Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Birmingham, AL on ClinicalTrials.gov.
Parkinson's disease studies recruiting in Birmingham
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Alabama- Birmingham ( Site 5015)
- Registry record
- NCT07216703 · updated
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- Phase 3
- Ages 50 to 85
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- University of Alabama at Birmingham
- Registry record
- NCT07174310 · updated
A Study of Buntanetap in Participants With PD
- Phase 2/3
- Ages 40 to 85
- All sexes
- Sponsor
- Annovis Bio Inc.
- Study site
- University of Alabama at Birmingham
- Registry record
- NCT07284784 · updated
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
- Phase 2/3
- Ages 40 to 80
- All sexes
- Sponsor
- Biohaven Therapeutics Ltd.
- Registry record
- NCT06976268 · updated
The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
- Phase 1/2
- Ages 30 and older
- All sexes
- Sponsor
- University of Alabama at Birmingham
- Study site
- UAB Advanced Imaging Facility
- Registry record
- NCT03457493 · updated
Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)
- Early Phase 1
- Ages 18 to 99
- All sexes
- Sponsor
- University of Alabama at Birmingham
- Registry record
- NCT06289582 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Birmingham, AL on ClinicalTrials.gov.
Multiple sclerosis (MS) studies recruiting in Birmingham
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
- Phase 4
- Ages 18 to 65
- All sexes
- Sponsor
- Genentech, Inc.
- Study site
- Alabama Neurology Associates
- Registry record
- NCT07609719 · updated
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Celgene
- Study site
- Alabama Neurology Associates
- Registry record
- NCT06782490 · updated
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- TG Therapeutics, Inc.
- Study site
- TG Therapeutics Investigational Trial Site
- Registry record
- NCT05877963 · updated
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Novartis Pharmaceuticals
- Study site
- Alabama Neurology Associates PC
- Registry record
- NCT07225504 · updated
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
- Phase 1
- Ages 18 to 65
- All sexes
- Sponsor
- University of Alabama at Birmingham
- Study site
- University of Alabama at Birmingham Medical Center
- Registry record
- NCT03759522 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Birmingham, AL on ClinicalTrials.gov.
Epilepsy studies recruiting in Birmingham
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Rapport Therapeutics Inc.
- Registry record
- NCT07563881 · updated
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
- Phase 3
- Ages 2 and older
- All sexes
- Sponsor
- Epygenix
- Study site
- University of Alabama at Birmingham
- Registry record
- NCT04462770 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Birmingham, AL on ClinicalTrials.gov.
Migraine studies recruiting in Birmingham
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Central Research Associates, LLC (CRA) dba Flourish Research
- Registry record
- NCT07645924 · updated
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Central Research Associates, LLC (CRA) dba Flourish Research
- Registry record
- NCT07674654 · updated
Responding With Evidence and Access for Childhood Headaches
- No phase
- Ages 10 to 17
- All sexes
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Study site
- University of Alabama at Birmingham Children's of Alabama
- Registry record
- NCT05889624 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Birmingham, AL on ClinicalTrials.gov.
Ask about studies near Birmingham
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.
CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections